DBI-001 is under clinical development by DermBiont and currently in Phase II for Tinea Pedis (Athlete Foot). According to GlobalData, Phase II drugs for Tinea Pedis (Athlete Foot) have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how DBI-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DBI-001 is under development for the treatment of tinea pedis (interdigital), tinea pedis (moccasin). It is administered as topically. The drug candidate is composed of single strain live bacteria Janthinobacterium lividum (human derived strain) in an aqueous gel formulation. It is being developed based on microbiome-based therapeutic platform.
It was also under development for the treatment of atopic dermatitis, onychomycosis.
DermBiont, Inc., a clinical stage precision dermatology company targeting skin diseases at their root cause. The company is headquartered in United States.
For a complete picture of DBI-001’s drug-specific PTSR and LoA scores, buy the report here.